AINDEX
Markets

Avalyn Pharma Inc. (AVLN)

AVLNNASDAQ-GSBiotechnology: Pharmaceutical Preparations

$29.79

-0.4900 (-1.62%) today

Regular session, Nov 16, 10:46 AM ET

-1.62% 1D
Market cap
$1.33bn
P/E
–
EPS, last 4 quarters
–
Dividend yield
–
Day range
$29.15 to $30.43
52-week range
$22.24 to $40.17
Average volume
–
Previous close
$30.28

Analysts

3 covering

Buy3 buy, 0 hold, 0 sell

Targets a year out average $56.50, +89.7% from here

$53.00now $29.79$60.00

Earnings

next estimate $-0.6700

Next report

Mar 2026

-33.3%

Jun 2026

+4.8%

Sep 2026

-4.7%

estimate reported, and the surprise

News

8 latest

The company

Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The Company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn's AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has indicated encouraging safety and clinical activity across Phase 1b and multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn's AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF).

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ-GS
Region
North America

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.